SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-005171
Filing Date
2023-01-10
Accepted
2023-01-10 07:06:33
Documents
14
Period of Report
2023-01-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d447672d8k.htm   iXBRL 8-K 26954
2 EX-99.1 d447672dex991.htm EX-99.1 29673
6 GRAPHIC g447672dsp1.jpg GRAPHIC 5765
  Complete submission text file 0001193125-23-005171.txt   196414

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kymr-20230110.xsd EX-101.SCH 2853
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kymr-20230110_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kymr-20230110_pre.xml EX-101.PRE 11263
8 EXTRACTED XBRL INSTANCE DOCUMENT d447672d8k_htm.xml XML 3360
Mailing Address 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472
Business Address 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

IRS No.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39460 | Film No.: 23519676
SIC: 2836 Biological Products, (No Diagnostic Substances)